Marksans Pharma Limited (NSE:MARKSANS)
178.20
-6.09 (-3.30%)
Aug 14, 2025, 3:30 PM IST
Marksans Pharma Revenue
Marksans Pharma had revenue of 6.20B INR in the quarter ending June 30, 2025, with 4.97% growth. This brings the company's revenue in the last twelve months to 26.52B, up 16.94% year-over-year. In the fiscal year ending March 31, 2025, Marksans Pharma had annual revenue of 26.23B with 20.46% growth.
Revenue (ttm)
26.52B
Revenue Growth
+16.94%
P/S Ratio
3.05
Revenue / Employee
14.41M
Employees
1,840
Market Cap
80.93B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 26.23B | 4.45B | 20.46% |
Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
Mar 31, 2021 | 13.76B | 2.42B | 21.32% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 537.77B |
Divi's Laboratories | 96.52B |
Cipla | 274.80B |
Apollo Hospitals Enterprise | 225.51B |
Mankind Pharma | 129.10B |
Zydus Lifesciences | 236.08B |
Fortis Healthcare | 80.94B |
Alkem Laboratories | 133.04B |
Marksans Pharma News
- 2 days ago - Marksans Pharma shares drop 13% as Q1 net profit falls 34.3% YoY to Rs 58.3 crore, revenue down 5% YoY - Business Upturn
- 6 days ago - Marksans Pharma subsidiary gets USFDA final approval for 20 mg Omeprazole Delayed-Release Tablets - Business Upturn
- 6 weeks ago - Marksans Pharma receives EIR from USFDA for Time-Cap Labs facility - Business Upturn
- 2 months ago - Marksans Pharma’s UK subsidiary secures approval for Oxybutynin Hydrochloride oral solution - Business Upturn
- 2 months ago - Marksans Pharma shares jump 3% after large block deal worth Rs 257 crore - Business Upturn
- 2 months ago - Marksans Pharma Block Deal: Over 1 crore shares worth Rs 257 crore change hands at Rs 249.95 per share - Business Upturn
- 2 months ago - Marksans Pharma’s subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution - Business Upturn
- 3 months ago - Marksans Pharma’s UK arm gets marketing approval for Sennosides 7.5 mg tablets - Business Upturn